4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.70 Consensus Price Target from Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received an average rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.25.

A number of brokerages have recently weighed in on FDMT. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Leerink Partners reissued an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th.

Insiders Place Their Bets

In other news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the transaction, the insider owned 3,594 shares of the company’s stock, valued at $43,128. The trade was a 42.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders have sold 6,337 shares of company stock valued at $70,649. 9.60% of the stock is currently owned by corporate insiders.

Institutional Trading of 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the first quarter worth approximately $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth $41,000. Los Angeles Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Quadrature Capital Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter worth $42,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $7.61 on Friday. The stock has a market cap of $434.76 million, a price-to-earnings ratio of -2.03 and a beta of 2.99. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $12.34. The business has a fifty day moving average of $9.51 and a 200-day moving average of $7.98.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.01. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. On average, equities research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.